/TEVA
TEVA Stock - Teva Pharmaceutical Industries Limited
Healthcare|Drug Manufacturers - Specialty & GenericNYSE
$30.35+0.10%
+$0.03 (+0.10%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).69
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+9.6%upside
Target: $33.26
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TEVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$30.05 – $30.65
TARGET (TP)$33.25
STOP LOSS$27.92
RISK/REWARD1:1.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.67
52W High$30.56
52W Low$12.47
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B |
| Gross Profit | $8.06B | $7.64B | $6.97B | $7.59B | $7.73B |
| Gross Margin | 48.7% | 48.2% | 46.7% | 47.8% | 46.4% |
| Operating Income | $-303,000,000 | $433.00M | $-2,197,000,000 | $1.72B | $-3,572,000,000 |
| Net Income | $-1,639,000,000 | $-559,000,000 | $-2,446,000,000 | $417.00M | $-3,990,000,000 |
| Net Margin | -9.9% | -3.5% | -16.4% | 2.6% | -24.0% |
| EPS | $-1.45 | $-0.50 | $-2.20 | $0.38 | $-3.64 |
Company Overview
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
56%
Hold / Neutral
7
39%
Sell / Underperform
1
6%
Analyst Consensus🟡 Mixed
10 Bullish8 Neutral/Bearish
Price Targets
$16
Average Target
↓ 47.3% Downside
Now
$7
Low
$16
Average
$35
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $35 |
| December 5th 2025 | Scotiabank | Initiation | Sector Outperform | $35 |
| June 6th 2025 | Goldman | Initiation | Buy | $24 |
| May 28th 2025 | Truist | Initiation | Buy | $25 |
| May 12th 2025 | JP Morgan | Upgrade | Overweight | $23 |
| July 10th 2024 | Argus | Upgrade | Buy | $20 |
| March 8th 2024 | JP Morgan | Upgrade | Neutral | $14 |
| February 12th 2024 | Piper Sandler | Upgrade | Overweight | $19← $12 |
| January 23rd 2024 | Jefferies | Upgrade | Buy | $14← $10 |
| January 3rd 2024 | Piper Sandler | Upgrade | Neutral | $12← $8 |
| December 18th 2023 | HSBC Securities | Initiation | Buy | $13 |
| November 27th 2023 | UBS | Upgrade | Buy | $13← $11 |
| July 6th 2023 | UBS | Upgrade | Neutral | $8← $7 |
| May 25th 2023 | Morgan Stanley | Initiation | Equal Weight | $10 |
| May 18th 2023 | Evercore ISI | Upgrade | Outperform | - |
Earnings History & Surprises
TEVABeat Rate
67%
Last 18 quarters
Avg Surprise
+3.7%
EPS vs Estimate
Beats / Misses
12/4
2 met exactly
Latest EPS
$0.78
Q4 2025
EPS Surprise History
Q1 24
+33.3%
$1.00vs$0.75
Q2 24
-5.9%
$0.48vs$0.51
Q3 24
+7.0%
$0.61vs$0.57
Q4 24
+6.2%
$0.69vs$0.65
Q1 25
+2.9%
$0.71vs$0.69
Q2 25
+10.6%
$0.52vs$0.47
Q3 25
+4.8%
$0.66vs$0.63
Q4 25
+14.7%
$0.78vs$0.68
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Jan 28, 2026 | $0.65 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.68 | $0.78 | +14.7% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.63 | $0.66 | +4.8% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.47 | $0.52 | +10.6% | ✓ BEAT |
Q1 2025 | Jan 29, 2025 | $0.69 | $0.71 | +2.9% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.65 | $0.69 | +6.2% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.57 | $0.61 | +7.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.51 | $0.48 | -5.9% | ✗ MISS |
Q1 2024 | Jan 31, 2024 | $0.75 | $1.00 | +33.3% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.60 | $0.60 | 0.0% | = MET |
Q3 2023 | Aug 2, 2023 | $0.54 | $0.56 | +3.7% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $0.57 | $0.40 | -29.8% | ✗ MISS |
Q1 2023 | Feb 8, 2023 | $0.68 | $0.71 | +4.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.61 | $0.59 | -3.3% | ✗ MISS |
Q3 2022 | Jul 26, 2022 | $0.57 | $0.68 | +19.3% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $0.55 | $0.55 | 0.0% | = MET |
Q1 2022 | Feb 9, 2022 | $0.74 | $0.77 | +4.1% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $0.65 | $0.59 | -9.2% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $0.57 | $0.59 | +3.5% | ✓ BEAT |
Latest News
Goldman Sachs Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $35
📈 PositiveBenzinga•Dec 19, 2025, 05:08 PM
Alvotech And Teva Reach US Settlement With Regeneron For AVT06 Proposed Biosimilar To Eylea Setting License Entry In Q4 2026
📈 PositiveBenzinga•Dec 19, 2025, 08:45 AM•Also: ,
Sagimet rises as licensing deal with Teva unit targets Madrigal drug
📈 PositiveSeeking Alpha•Dec 17, 2025, 06:06 PM
Sagimet Biosciences shares are trading higher after the company announced a license agreement with Teva subsidiary TAPI for Resmetirom API.
📈 PositiveBenzinga•Dec 17, 2025, 05:19 PM•Also:
Sagimet Biosciences Announced A License Agreement With A Subsidiary Of Teva Pharmaceutical
📈 PositiveBenzinga•Dec 17, 2025, 12:06 PM•Also:
JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $35
📈 PositiveBenzinga•Dec 16, 2025, 04:08 PM
Teva Removes Over 200 Improper Patent Listings Under Pressure From FTC; FTC Investigation Prompts Teva Request For Removal Of Patents From Orange Book, Paving The Way For Generic Competition
📉 NegativeBenzinga•Dec 10, 2025, 04:47 PM
B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $32
📈 PositiveBenzinga•Dec 9, 2025, 05:57 PM
Barclays Initiates Coverage On Teva Pharmaceutical Indus with Overweight Rating, Announces Price Target of $35
📈 PositiveBenzinga•Dec 9, 2025, 04:24 PM•Also:
Teva Pharmaceuticals Submits New Drug Application To FDA For Olanzapine Extended-Release Injectable Suspension For Treatment Of Schizophrenia In Adults
📈 PositiveBenzinga•Dec 9, 2025, 01:03 PM
Goldman Sachs Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $31
📈 PositiveBenzinga•Dec 8, 2025, 04:36 PM
Scotiabank Initiates Coverage On Teva Pharmaceutical Indus with Sector Outperform Rating, Announces Price Target of $35
📈 PositiveBenzinga•Dec 5, 2025, 03:03 PM
Teva Pharmaceuticals International GmbH Wins EU Approval For Denosumab Biosimilars PONLIMSI And DEGEVMA
📈 PositiveBenzinga•Nov 25, 2025, 01:11 PM
Teva Pharmaceutical Industries Unveils Teva Rise Innovation Platform
📈 PositiveBenzinga•Nov 19, 2025, 01:08 PM
Teva Pharmaceuticals Industries Presents New Data From The Ongoing, Real-World IMPACT-TD Registry; In A New Cohort Of 27 Adults From The IMPACT-TD Registry, Up To 77% Of Participants Reported Improvements In Aspects Of Their Lives Impacted By Tardive Dyskinesia While Taking AUSTEDO Or AUSTEDO XR
📈 PositiveBenzinga•Nov 7, 2025, 11:04 PM
JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $28
📈 PositiveBenzinga•Nov 6, 2025, 10:05 PM
Teva Canada Says Welcomes Health Canada Announcement RAMQ Reimbursement Update
📈 PositiveBenzinga•Nov 6, 2025, 01:08 PM
Teva Pharm CEO Francis Tells Reuters Co. Well Positioned On Potential US Tariffs, Teva Has 9 Manufacturing Plants
📈 PositiveBenzinga•Nov 5, 2025, 03:06 PM
Teva gains after Q3 beat and guidance hike
📈 PositiveSeeking Alpha•Nov 5, 2025, 01:16 PM
Teva Pharmaceutical Industries shares are trading higher after the company beat Q3 earnings and revenue estimates and raised its full-year EPS guidance.
📈 PositiveBenzinga•Nov 5, 2025, 12:25 PM
Frequently Asked Questions about TEVA
What is TEVA's current stock price?
Teva Pharmaceutical Industries Limited (TEVA) is currently trading at $30.35 per share. The stock has moved +0.10% today.
What is the analyst price target for TEVA?
The average analyst price target for TEVA is $33.25, based on 1 analyst.
What sector is Teva Pharmaceutical Industries Limited in?
Teva Pharmaceutical Industries Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NYSE exchange.
What is TEVA's market cap?
Teva Pharmaceutical Industries Limited has a market capitalization of $34.81 billion, making it a large-cap company.
Does TEVA pay dividends?
No, Teva Pharmaceutical Industries Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIIB
Biogen Inc.
$174.80
Mkt Cap: $25.6B
BNTX
BioNTech SE
$92.50
Mkt Cap: $22.2B
DXCM
DexCom, Inc.
$66.06
Mkt Cap: $25.8B
LH
Labcorp Holdings Inc.
$252.03
Mkt Cap: $20.9B
NBIX
Neurocrine Biosciences, Inc.
$145.00
Mkt Cap: $14.4B
NTRA
Natera, Inc.
$231.96
Mkt Cap: $32.0B
PHG
Koninklijke Philips N.V.
$26.66
Mkt Cap: $25.4B
PODD
Insulet Corporation
$289.62
Mkt Cap: $20.4B
STE
STERIS plc
$254.34
Mkt Cap: $25.0B
WAT
Waters Corporation
$378.03
Mkt Cap: $22.5B
Explore stocks similar to TEVA for comparison